Zacks Investment Research Downgrades Enanta Pharmaceuticals (NASDAQ:ENTA) to Hold

Zacks Investment Research lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a strong-buy rating to a hold rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Other analysts also recently issued reports about the stock. Berenberg Bank set a €126.00 ($146.51) price objective on shares of Nemetschek and gave the company a neutral rating in a research report on Tuesday, April 23rd. BidaskClub raised shares of Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. Finally, Wolfe Research initiated coverage on shares of Enanta Pharmaceuticals in a research report on Friday, May 24th. They set an outperform rating and a $117.00 price objective on the stock. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Enanta Pharmaceuticals currently has an average rating of Buy and an average price target of $111.20.



Shares of ENTA stock opened at $82.00 on Wednesday. Enanta Pharmaceuticals has a one year low of $64.08 and a one year high of $125.68. The company’s 50-day moving average price is $87.39. The stock has a market cap of $1.61 billion, a P/E ratio of 23.56 and a beta of 1.03.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The company had revenue of $39.60 million for the quarter, compared to the consensus estimate of $40.92 million. During the same period in the prior year, the firm posted $0.61 EPS. Enanta Pharmaceuticals’s revenue for the quarter was down 10.0% on a year-over-year basis. On average, analysts forecast that Enanta Pharmaceuticals will post 1.88 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in ENTA. WINTON GROUP Ltd grew its holdings in shares of Enanta Pharmaceuticals by 33.8% in the second quarter. WINTON GROUP Ltd now owns 6,095 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 1,539 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Enanta Pharmaceuticals by 11.9% in the first quarter. First Trust Advisors LP now owns 25,234 shares of the biotechnology company’s stock valued at $2,410,000 after purchasing an additional 2,681 shares in the last quarter. FMR LLC boosted its stake in Enanta Pharmaceuticals by 19.5% during the first quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock worth $22,944,000 after buying an additional 39,200 shares during the period. Marshall Wace North America L.P. boosted its stake in Enanta Pharmaceuticals by 1,128.7% during the first quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock worth $21,558,000 after buying an additional 207,326 shares during the period. Finally, Trexquant Investment LP purchased a new position in Enanta Pharmaceuticals during the first quarter worth $1,433,000. 89.50% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: What is the Moving Average Convergence Divergence (MACD) oscillator?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.